ENJAYMO: payments to doctors
Payments that named ENJAYMO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1M
- Providers
- 3,945
- Transactions
- 7,661
- Average per transaction
- $131
The per-transaction average — $131 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 3,945 providers the average total is $254, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sanofi | $806,602 | 80.5% |
| Recordati_rare_diseases_inc. | $176,698 | 17.6% |
| Sanofi-aventis U.S. LLC | $19,141 | 1.9% |